Neurogene Inc. (NGNE)
Neurogene Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Neurogene Inc. (NGNE) is a Biotechnology company based in US with a market capitalization of $579.6M. Free cash flow was negative at -$78.4M. This page tracks NGNE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 107 employees · IPO Mar 7, 2014
Valuation
Valuation & price
$29.82as of May 17, 2026· -30.4% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
2.19
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$579.6M
Market cap
—
Revenue growth (YoY)
-251.0%
Gross margin
-$78.4M
Free cash flow (USD)
-$259.1M
Net debt
Net cash position
20.5%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
3
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- Insider sellJul 7, 2026Filing
Insider Sell $173K · 10b5-1 PlanCvijic Christine Mikail · Director, President and CFO · $173.4K
- Insider sellJul 2, 2026Filing
Insider Sell $167K · 10b5-1 PlanCvijic Christine Mikail · Director, President and CFO · $166.6K
- 8-K eventJul 1, 2026Filing
Public Offering Announced
- 8-K eventJun 29, 2026Filing
Phase 1/2 Trial Update
- 8-K eventJun 8, 2026Filing
Corporate Presentation Released
- 8-K eventJun 4, 2026Filing
Annual Meeting Results
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- 8-K eventMay 12, 2026Filing
Corporate Presentation Released
- Insider sellMay 8, 2026Filing
Insider Sell $300K · 10b5-1 PlanCvijic Christine Mikail · Director, President and CFO · $300K
- 8-K eventApr 20, 2026Filing
Board Expansion and Appointments
Questions
Frequently asked questions
What is Neurogene Inc.'s market cap?
Neurogene Inc. (NGNE) has a market capitalization of $579.6M.
What is NGNE's P/E ratio?
A meaningful P/E ratio is not available for NGNE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is NGNE's price-to-book (P/B) ratio?
NGNE trades at 2.19 times book value per share.
Are insiders buying NGNE stock?
SEC Form 4 filings show no open-market insider buys at Neurogene Inc. in the last 90 days (3 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.